What drugs does INTRA-CELLULAR make?

INTRA-CELLULAR has 1 FDA-approved drugs including CAPLYTA.

What therapeutic areas does INTRA-CELLULAR focus on?

INTRA-CELLULAR focuses primarily on Neurology and Cardiovascular.

← Back

Data updated: Mar 29, 2026

INTRA-CELLULAR

NeurologyCardiovascular

Pharma

INTRA-CELLULAR is a pharmaceutical company focused on Neurology, Cardiovascular. Key products include CAPLYTA.

2019

Since

Drugs

Trials

Approved (2yr)

Key Drugs

CAPLYTA

lumateperone tosylate

CNS

5-HT2A 3 indications · 2019

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Competitive Matchups ProEarly access

Recent Activity

CAPLYTA 2025-11-05

Efficacy

SEC Filings ProEarly access

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 92%

0 drugs Phase 3: 1 Phase 2: 3 Phase 1: 1

Cardiovascular 8%

0 drugs Phase 1: 1

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

GE HEALTHCARE specialty

Neurology, Cardiovascular

Novo Nordisk big-pharma

Cardiovascular, Neurology

LEDERLE big-pharma

Cardiovascular, Neurology

PAI HOLDINGS PHARM big-pharma

Neurology, Cardiovascular

VALIDUS PHARMS specialty

Cardiovascular, Neurology

INTRA-CELLULAR

Key Drugs

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Competitive Matchups ProEarly access

Recent Activity

Therapeutic Areas

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

All Drugs (1)

Active (1)

Discontinued (0)

Company Info

INTRA-CELLULAR

Set Alert

Key Drugs

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Competitive Matchups ProEarly access

Recent Activity

Therapeutic Areas

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

All Drugs (1)

Active (1)

Discontinued (0)

Company Info